Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards
Preprint
- 22 July 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
The World Health Organization (WHO) has highlighted the importance of an international standard (IS) for SARS-CoV-2 neutralizing antibody titer detection, with the aim of calibrating different diagnostic techniques. In this study, IS was applied to calibrate neutralizing antibody titers (IU/mL) and binding antibody titers (BAU/mL) in response to SARS-CoV-2 vaccines. Serum samples were collected from participants receiving the Moderna (n = 20) and Pfizer (n = 20) vaccines at three time points: pre-vaccination, after one dose, and after two doses. We obtained geometric mean titers of 1404.16 and 928.75 IU/mL for neutralizing antibodies after two doses of the Moderna and Pfizer vaccines, respectively. These values provide an important baseline for vaccine development and the implementation of non-inferiority trials. We also compared three commercially available kits from Roche, Abbott, and MeDiPro for the detection of COVID-19 antibodies based on binding affinity to S1 and/or RBD. Our results demonstrated that antibody titers measured by commercial assays are highly correlated with neutralizing antibody titers calibrated by IS.Keywords
This publication has 19 references indexed in Scilit:
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysNature Protocols, 2021
- Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 SubjectsViruses, 2021
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraCell, 2021
- Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal studyThe Lancet Microbe, 2021
- WHO International Standard for anti-SARS-CoV-2 immunoglobulinThe Lancet, 2021
- SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidatesnpj Vaccines, 2021
- Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing TitersJournal of Clinical Microbiology, 2021
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interactionNature Biotechnology, 2020